Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

Adhesive Capsulitis Clinical Trial

Official title:

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis (RANGE)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04160091
• Other study ID #: FX006-2018-016
• Status: Terminated
• Phase: Phase 2
• Start date: November 7, 2019
• Est. completion date: June 15, 2020

Study information

• Verified date: January 2024
• Source: Pacira Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind study to evaluate the efficacy and safety of FX006 in patients with glenohumeral osteoarthritis (OA) or shoulder adhesive capsulitis (AC).

Description:

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in separate cohorts of patients with a documented history of either glenohumeral OA or shoulder AC. Glenohumeral OA and shoulder AC patients will be randomized to receive a single intra-articular injection of either FX006 or placebo (saline) in a 1:1 ratio to the index shoulder with a 24-week Treatment Evaluation Period. Glenohumeral OA patients will be stratified by Baseline average daily shoulder pain with movement score according to the following classifications: 5.0 to <7.0 or ≥7.0 to 9.0 (0 to 10 numeric rating scale [NRS]). Shoulder AC patients will be stratified by Baseline average daily shoulder pain with movement score according to the following classifications: 5.0 to <7.0 or ≥7.0 to 9.0 (0 to 10 NRS), and by pain duration since onset (1 to 3 months, inclusive, or >3 to ≤6 months). A Home Exercise Program will be implemented 3 days following injection for shoulder AC patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 19
• Est. completion date: June 15, 2020
• Est. primary completion date: June 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 80 Years

Eligibility

Inclusion Criteria:

Glenohumeral OA:

• Male or female, 35 to 80 years of age, inclusive, on the day of consent.

• Painful symptoms associated with OA of the index glenohumeral joint for =3 months prior to the Screening Visit.

• Grade 2 or 3 OA in the index glenohumeral joint based on the Samilson-Prieto classification system as confirmed by X-ray (axillary view and true anterior-posterior view) taken at the Screening Visit.

Shoulder AC:

• Male or female, 35 to 80 years of age, inclusive, on the day of consent.

• Pain associated with AC of the index joint for =1 month but = 6 months prior to the Screening Visit.

• Limitations on both active and passive ROM =25% in at least 2 directions (e.g., forward flexion, abduction, and internal and external rotation assessed in a standardized protocol) compared with the contralateral shoulder or with normal values.

• No X-ray evidence of OA of the index shoulder (axillary view and true anterior-posterior view) at the Screening Visit.

• Agrees to complete a standardized, protocol-specified shoulder Home Exercise Program (HEP) starting 3 days after injection until the End of Study (EOS) Visit.

Both:

• Written consent to participate in the study

• Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions

• (BMI) = 40 kg/m2

• Average daily mean shoulder pain with movement score =5.0 and =9.0 in the index shoulder (0 to 10 NRS) using the average daily ratings for at least 5 out of the 7 days prior to Day 1.

• Shoulder pain present >15 days in the month prior to the Screening Visit

• Willing to complete a washout of protocol-specified excluded medications 7 days prior to Day 1 and abstain from use of protocol-specified excluded medications throughout the study

• Willing to abstain from nonpharmacological therapies for the index joint for 2 weeks prior to Day 1 and throughout the study.

Exclusion Criteria:

• Has both glenohumeral OA and shoulder AC

• Has bilateral AC

• Has bilateral glenohumeral OA with glenohumeral OA pain of the shoulder contralateral to the index shoulder >3.0 (0 to 10 NRS) within 1 month prior to the Screening Visit

• Has a history of arthritis in other joints of the index shoulder (as confirmed by medical history and physical exam)

• Has a history or suspicion of full thickness rotator cuff tear in the index shoulder within 6 months of the Screening Visit

• Has symptomatic partial rotator cuff tear, tendinopathy, tendonitis, or bursitis in the index shoulder within 6 months of the Screening Visit

• Has a subchondral bone insufficiency fracture or humeral head necrosis/collapse in the index shoulder

• Shoulder AC patients only: Has a history of shoulder surgery or radiotherapy

• Glenohumeral OA patients only: Has a previous shoulder injury with functional limitation =1 month or surgery within 52 weeks of the Screening Visit

• Has an index shoulder with major dysplasia or congenital abnormality, osteochondritis dissecans, acromegaly, ochronosis, hemochromatosis, Wilson's disease, or primary osteochondromatosis, or a history of avascular necrosis with secondary OA

• Has current or history of infection in the index shoulder or current skin infection at injection site

• Has a concurrent chronic pain condition with a pain score >3.0 (0 to 10 NRS) within 1 month prior to the Screening Visit

• Has a history or current evidence of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease, systemic lupus erythematosus, calcium pyrophosphate dihydrate crystal deposition disease (CPPD), or other autoimmune diseases

• Has any planned surgeries in the upper limbs during the study or any other surgery during the study that would require use of a restricted medication

• Has surgical hardware or other foreign body present in the index shoulder

• Has received an IA corticosteroid of any joint within 3 months of the Screening Visit

• Has received an IA treatment of the index shoulder with any of the following agents within 6 months of the Screening Visit

• Has received intravenous (IV), intrabursal, intratendinous, intramuscular (IM) or epidural corticosteroids within 3 months of the Screening Visit

• Has received oral corticosteroids within 1 month of the Screening Visit

• Has received inhaled, intranasal, or topical corticosteroids within 2 weeks of the Screening Visit

• Has had significant changes to lifestyle with regard to physical activity and lifestyle within 1 month of the Screening Visit or any planned changes throughout the duration of the study

• Has known hypersensitivity to TA or PLGA

• Has laboratory evidence of infection with (HIV), a positive test for hepatitis B surface antigen (HBsAg), or positive serology for hepatitis C virus (HCV) with positive test for HCV ribonucleic acid

• Has an electrocardiogram (ECG) abnormality

• Has uncontrolled diabetes as indicated by a hemoglobin A1c of >8% (>59 mmol/mol).

• Has a history of sarcoidosis or amyloidosis

• Has a history of or active Cushing's syndrome

• Has used chemotherapeutic agents, immunomodulators, or immunosuppressants within 5 years of the Screening Visit

• Has current or history of malignancy within 5 years prior to the Screening Visit, except for basal or squamous cell carcinoma of the skin or cervical carcinoma in situ that has been treated successfully.

• Has active substance use disorder or history of substance use disorder within 12 months prior to the Screening Visit

• Has received a live or live attenuated vaccine within 3 months of the Screening Visit

• Has used any other investigational drug, biologic, or device within 3 months of the Screening Visit

• Has any infection requiring IV antibiotics 4 weeks prior to Day 1 or oral antibiotics 2 weeks prior to Day 1

• Has a contraindication to the use of acetaminophen

• Is a female that is pregnant or nursing or plans to become pregnant during the study; or is a male who plans to inseminate a partner or donate sperm during the study

Related Conditions & MeSH terms

• Adhesive Capsulitis
• Bursitis
• Osteoarthritis
• Osteoarthritis of the Shoulder

Intervention

Drug:
• FX006
Single intra-articular injection
• Normal Saline
Single intra-articular injection

Locations

Country	Name	City	State
United States	University Orthopedics Center	Altoona	Pennsylvania
United States	Texas Orthopedic Specialists	Bedford	Texas
United States	Hassman Research Institute	Berlin	New Jersey
United States	Affinity Orthopedic Specialists	Birmingham	Alabama
United States	Alabama Clinical Therapeutics, LLC	Birmingham	Alabama
United States	Central Research Associates	Birmingham	Alabama
United States	Coastal Orthopaedics and Sports Medicine	Bradenton	Florida
United States	South Lake Pain Institute	Clermont	Florida
United States	Spectrum Medical, Inc.	Danville	Virginia
United States	Mountain View Clinical Research Center	Denver	Colorado
United States	Altoona Center for Clinical Research	Duncansville	Pennsylvania
United States	M3 Emerging Medical Research	Durham	North Carolina
United States	TriWest Research Associates	El Cajon	California
United States	CORE Orthopedic Medical Center	Encinitas	California
United States	Universal Axon Clinical Research	Homestead	Florida
United States	Centex Studies, Inc.	Houston	Texas
United States	BioSolutions Clinical Research Center	La Mesa	California
United States	Precision Clinical Research	Lauderdale Lakes	Florida
United States	Infinite Clinical Research	Miami	Florida
United States	Coastal Clinical Research, Inc.	Mobile	Alabama
United States	Better Health Clinical Research, Inc.	Newnan	Georgia
United States	Jewitt Orthopedic Center	Orlando	Florida
United States	Arizona Research Center	Phoenix	Arizona
United States	Gulfcoast Research Institute	Sarasota	Florida
United States	Tucson Orthopaedic Institute	Tucson	Arizona
United States	Arthritis and Rheumatism Associates PC	Wheaton	Maryland
United States	Professional Research Network of Kansas, LLC	Wichita	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
Pacira Pharmaceuticals, Inc	Medpace, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Curve of the Change From Baseline in the Weekly Mean of the Daily Shoulder Pain With Movement	The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates "No pain" and 10 indicates "Worst possible pain."	Baseline to 8 weeks
Secondary	Change From Baseline in the Weekly Mean of the Average Daily Shoulder Pain With Movement Score	The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates "No pain" and 10 indicates "Worst possible pain."	Baseline to 12 weeks
Secondary	Change From Baseline in the SPADI Pain Subscale at Week 12	Shoulder Pain and Disability Index (SPADI) Pain scale is measured using 5 11-point NRS questions where 0 indicates "no pain" and 10 indicates "worst pain imaginable." The Pain and Disability Subscales are presented as a percentage of the total possible score. The Total SPADI score ranges from 0 (best) to 100 (worst) is computed by taking the means of the Pain and Disability Subscale scores.	Baseline to 12 weeks
Secondary	Change From Baseline in the SPADI Disability Subscale at Week 12	Shoulder Pain and Disability Index (SPADI) Disability scale is measured using 8 11-point NRS questions where 0 indicates "no difficulty" and 10 indicates "so difficult it requires help." The Pain and Disability Subscales are presented as a percentage of the total possible score. The Total SPADI score ranges from 0 (best) to 100 (worst) is computed by taking the means of the Pain and Disability Subscale scores.	Baseline to 12 weeks
Secondary	Patient Global Impression of Change (PGIC) Score at Week 12	PGIC is measured using a 7-point NRS where 1 indicates "very much improved" and 7 indicates "very much worse."	Baseline to 12 weeks
Secondary	Change From Baseline in the Range of Motion (ROM) of Active External Rotation at Week 12	Measured using a goniometer which is a device that measures ROM joint angles	Baseline to 12 weeks